Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells by Karamitros, D et al.
 1
Heterogeneity of human lympho-myeloid progenitors at the single cell level 1 
Dimitris Karamitros1,2¶, Bilyana Stoilova1,2¶, Zahra Aboukhalil1, Fiona Hamey3§, Andreas 2 
Reinisch4§, Marina Samitsch1, Lynn Quek1,2,5, Georg Otto1, Emmanouela Repapi1, Jessica 3 
Doondeea1,2, Batchimeg Usukhbayar1,2, Julien Calvo6, Stephen Taylor1, Nicolas Goardon1, 4 
Emmanuelle Six7, Francoise Pflumio6, Catherine Porcher1, Ravindra Majeti4, Berthold 5 
Gottgens3, Paresh Vyas1,2,5* 6 
1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine and 7 
2Oxford Biomedical Research Centre, University of Oxford, UK; 3Department of Haematology 8 
and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of 9 
Cambridge, Cambridge, UK; 4Division of Hematology, Stanford Institute for Stem Cell Biology 10 
and Regenerative Medicine, Stanford, CA, USA; 5Department of Hematology, OUH NHS 11 
Trust, UK; 6UMR967 INSERM/CEA/Université Paris 7/Université Paris 11, Paris, France; 12 
7UMR1163, Paris Descartes–Sorbonne Paris Cité University, Imagine Institute, Paris, 13 
France. ¶These authors contributed equally to this work and are listed alphabetically. §These 14 
authors contributed equally to this work. 15 
*Corresponding author: Paresh Vyas, MRC Molecular Haematology Unit, MRC Weatherall 16 
Institute of Molecular Medicine and Department of Haematology, University of Oxford OX3 17 
9DS, UK. Telephone: +44-1865-222309. Fax: +44-1865 222501. E- mail: 18 
paresh.vyas@imm.ox.ac.uk.  19 
 20 
Abstract 115 words 21 
Total length: 4447 words 22 
  23 
 2
Abstract 24 
The human hemopoietic progenitor hierarchy producing lymphoid and granulocytic-25 
monocytic (myeloid) lineages is unclear. Multiple progenitor populations produce lymphoid 26 
and myeloid cells, but remain incompletely characterized. Here, we demonstrated cord blood 27 
lympho-myeloid containing progenitor populations - the lymphoid-primed multi-potential 28 
progenitor (LMPP), granulocyte-macrophage progenitor (GMP) and multi-lymphoid 29 
progenitor (MLP) - were functionally and transcriptionally distinct and heterogeneous at the 30 
clonal level, with progenitors of many different functional potentials present. Though most 31 
progenitors had uni-lineage myeloid or lymphoid potential, bi- and rarer multi-lineage 32 
progenitors occurred in LMPP, GMP and MLP. This, coupled with single cell expression 33 
analyses, suggested a continuum of progenitors execute lymphoid and myeloid 34 
differentiation rather than only uni-lineage progenitors being present downstream of stem 35 
cells. 36 
  37 
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Human hemopoiesis produces 10 billion new, terminally mature, blood cells daily; a 38 
production that is also rapidly responsive to external change. Most of this production 39 
generates red cells, short-lived myeloid cells and platelets. It also replenishes long-lived 40 
acquired immune cells and innate immune natural killer (NK) cells. Dysregulation of this 41 
complex process can lead to hemopoietic and immune deficiencies and blood cancers. Active 42 
debate continues about the heterogeneity and plasticity of hemopoietic cell populations, in 43 
steady state and in response to stimuli. At the hierarchy apex lie multi-potent hemopoietic 44 
stem cell (HSC) populations, heterogeneous with respect to differentiation potential, cell 45 
cycle, self-renewal capacity, stability over time and contribution to hemopoiesis in steady 46 
state versus transplantation1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11. Downstream of murine long-term HSCs are 47 
heterogeneous short-term HSC (HSCST), multipotent (MPP) and early lineage-biased 48 
progenitors5, 7, 12, 13, 14. The human HSCST/MPP population has not been fully defined15, 16. In 49 
terms of lineage potential restriction, the erythroid and megakaryocyte fates likely diverge 50 
early from other myeloid and lymphoid potentials in mouse14, 17, 18, 19, 20 and human21, 22, 23, 24, 25 51 
and may arise directly from either HSC6 or immediate downstream MPP14, 16, 26.  52 
Focusing on the first human lympho-myeloid progenitors downstream of HSC and MPP, two 53 
progenitor populations have been identified within the immature Lin-CD34+CD38-CD90-/lo 54 
compartment. These include a Lin-CD34+CD38-CD90-/loCD45RA+CD10- lymphoid-primed 55 
multi-potential progenitor (LMPP) with granulocytic, monocytic, B and T cell potential, but 56 
unable to generate erythrocytes or megakaryocytes22. These data support prior studies 57 
showing human CD34+CD10- cells retain lympho-myeloid potential, progressively losing 58 
myeloid potential with CD10 expression27, 28. In contrast, the multi-lymphoid progenitor (MLP), 59 
which was initially reported as Lin-CD34+CD38-CD90-/loCD45RA+CD10+, has lymphoid (B, T, 60 
NK), monocytic and dendritic cell (DC) potential but cannot make granulocytes21. However, 61 
recent CD10- MLP populations29 have been reported that may overlap with the LMPP. Within 62 
the Lin-CD34+CD38+CD45RA+ compartment, there are at least two lympho-myeloid 63 
progenitors: a CD62LhiCD10- lymphoid-primed progenitor with lymphoid, monocytic and DC 64 
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potential23 and the granulocyte-monocyte progenitor (GMP; Lin-65 
CD34+CD38+CD45RA+CD123+). GMP contains both CD62hi and CD62lo subpopulations and 66 
has mainly myeloid potential but retains residual lymphoid potential22, 30 consistent with the 67 
murine pre-GM progenitor31. Finally, the human Lin-CD34+CD38+CD45RA+ compartment also 68 
contains a CD10+ subpopulation with T, B, NK and DC potential but lacking myeloid 69 
potentials32.These prior observations raise questions about whether these progenitor 70 
populations are pure or heterogeneous, how distinct they are and the nature of the functional, 71 
transcriptional and hierarchical relationships between them.  72 
Taken together, lympho-myeloid progenitors have been described in the Lin-73 
CD34+CD45RA+CD90- compartment that can be either CD38+ or CD38- and CD10+ or CD10-. 74 
This led us to directly, and rigorously, compare the in vitro and in vivo functional potential and 75 
transcriptional programs of human LMPP, MLP and GMP. We have shown these progenitors 76 
are distinct and heterogeneous. Single cell gene expression demonstrated a continuum of 77 
progenitors with lymphoid and myeloid potential downstream of stem cells. Using novel flow 78 
purification strategies, the bulk of multi-lineage lympho-myeloid progenitors were contained 79 
within a sub-compartment of LMPP. 80 
Results 81 
In vitro assays reveal the potential of distinct lympho-myeloid progenitors 82 
We improved prior flow cytometric staining and sorting strategies21, 22 to prospectively purify 83 
eight human hemopoietic stem/progenitor cell (HSPC) populations (Supplementary Table 1, 84 
Supplementary Fig. 1a) in human cord blood (CB) and bone marrow (BM). These HSPC 85 
populations included: haematopoietic stem cells (HSC: Lin-CD34+CD38-CD90+CD45RA-86 
CD10-), multipotent progenitors (MPP: Lin-CD34+CD38-CD90-CD45RA-CD10-), lymphoid-87 
primed multipotent progenitor (LMPP: Lin-CD34+CD38-CD90-/loCD45RA+CD10-), multi-88 
lymphoid progenitor (MLP: Lin-CD34+CD38-CD90-/loCD45RA+CD10+), common myeloid 89 
progenitor (CMP: Lin-CD34+CD38+CD123+CD45RA-CD10-), granulocyte macrophage 90 
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progenitor (GMP: Lin-CD34+CD38+CD123+CD45RA+CD10-), megakaryocyte erythroid 91 
progenitor (MEP: Lin-CD34+CD38+CD123-CD45RA-CD10-) and B and NK cell progenitor 92 
(B/NK: Lin-CD34+CD38+CD90-CD45RA+CD10+). Within CB Lin-CD34+ cells these eight HSPC 93 
populations accounted for 82% of cells. The remaining cells did not constitute separate 94 
populations. The Lin-CD34+CD38-CD45RA+ compartment contained a mixture of CD10- 95 
LMPP and CD10+ MLP progenitors (Supplementary Fig. 1a). Furthermore, the more mature 96 
Lin-CD34+CD38+ compartment was separated into the CD10+ B-NK progenitor population32 97 
and CD10- heterogeneous myeloid progenitors. Immunophenotypic LMPP and MLP were 98 
rare (Supplementary Table 1). Using analysis gates they constituted 0.2% of the BM Lin-99 
CD34+ compartment and ~2/105 of BM mononuclear cells (MNCs). Though more frequent in 100 
CB, they still only constituted ~1/104 MNCs. GMPs were 20-fold more abundant in CB and 101 
100-fold more abundant in BM than LMPPs and MLPs (~1.5-2/103 MNCs). 102 
As the frequency of adult BM LMPP and MLP was extremely low, we used fresh CB cells as 103 
a source of HSPCs. Cells were double-sorted to high purity (>99%, except the CMP 97%). In 104 
methylcellulose-based colony forming unit assays the LMPP and MLP had low myeloid 105 
clonogenic potential (6% and <1%) compared to GMP (31%) (Fig. 1a-b). GMP and LMPP 106 
generated granulocytic (G), monocyte/macrophage (M) and GM colonies with either no, or 107 
minimal, erythroid (E) potential (<0.5%) (Fig. 1a). MLP only generated very few monocyte 108 
colonies (Fig. 1a), consistent with previous data15, 21, 22, 33.  109 
We analyzed the lymphoid and myeloid differentiation potential of a population of 150 LMPP, 110 
MLP and GMPs using an optimized, new in vitro liquid culture on MS-5 stroma supplemented 111 
with Stem Cell Factor (SCF), Granulocyte Colony Stimulating Factor (G-CSF), Fms-Related 112 
Tyrosine Kinase 3 Ligand (FLT3L), Interleukin 2 (IL2), IL15 and DUP-697 (SGF15/2 113 
condition). By performing a kinetic analysis of lineage outputs, we determined that 2 weeks 114 
was the optimal timing to detect hCD45+CD15+ neutrophils (G), hCD45+CD14+ monocytes 115 
(M), hCD45+CD19+ B cells and hCD45+CD56+ natural killer (NK) cells from the culture (Fig. 116 
1c and Supplementary Fig. 1b). Flow cytometry purified G, M, B or NK cells from SGF15/2 117 
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in vitro culture expressed appropriate lineage-affiliated genes (Fig. 1d, Supplementary 118 
Table 2). Therefore, we analyzed all subsequent limiting dilution and single cell cultures at 119 
week 2 to capture all four myeloid (G, M) and lymphoid (B, NK) outputs. We tested T cell 120 
production of LMPP, MLP and GMP populations at weeks 5 and 7 using an in vitro liquid 121 
culture assay on OP9-hDL1 stroma with SCF, FLT3L and IL7 (SF7a condition, Fig 1e, 122 
Supplementary Fig. 1c). LMPP, GMP and MLP generated hCD7+CD1a+ immature T cells, 123 
more mature hCD7+CD1a+hCD4+CD8+ double positive (DP), and hCD7+CD1a+CD4-CD8+ 124 
and hCD7+CD1a+CD4+CD8- single positive T cells. Flow cytometric purified T cell 125 
subpopulations expressed appropriate lineage-affiliated genes (Fig 1f, Supplementary 126 
Table 2).  127 
In summary, we established conditions to prospectively purify eight HSPC populations and 128 
test in vitro potential into myeloid and lymphoid lineages.  129 
Functional heterogeneity of lympho-myeloid progenitors 130 
We next used four in vitro liquid culture assays to test the clonal potential of CB LMPP, MLP 131 
and GMP (Supplementary Fig. 2a-b). First, limiting dilution assay (LDA) was performed in 132 
the SGF15/2 condition and lineage output assessed by flow cytometry (Supplementary Fig. 133 
2c). 1 in 2 LMPP cells produced B cells, 1 in 3 NK cells, but only 1 in 5 monocytes and 1 in 134 
10 granulocytes (Table 1, Supplementary Fig. 2d). GMPs generated myeloid cells with 135 
higher frequency (1 in 2 for M, 1 in 4 for G) and lymphoid cells at lower frequency (1 in 22 for 136 
B, 1 in 8 NK) (Table 1, Supplementary Fig. 2d). 1 in 11 MLP cells produced B cells and 1 in 137 
18 generated NK cells, whereas myeloid output was rare (Table 1), indicating that MLPs 138 
were lymphoid-biased. Bi-lineage and multi-lineage cells were detected at lower frequencies 139 
(1 in 6 to 1 in 789) (Table 1, Supplementary Table 3a).  140 
As limit dilution analysis does not rigorously define frequency of multi-lineage functional 141 
potential at a clonal level, we assessed lympho-myeloid (B, NK, G, M) potential, in the 142 
second assay, the optimized liquid culture SGF15/2 condition. We tested potential of 1136 143 
LMPPs, 710 MLP and 1622 GMPs as single cells, isolated from 22 biological CB donors 144 
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(totaling 6.3x109 MNCs), to provide robust quantitative data, especially for rare functional 145 
potentials (Supplementary Table 3b). At a single cell level, LMPP and GMP had higher 146 
cloning efficiency (54% and 71% respectively) than MLP (11%) (Fig. 2a). LMPP and MLP 147 
were primarily lymphoid progenitors, whereas GMP mainly a myeloid progenitor (Fig. 2a). 148 
Focusing on productive wells, 69% of LMPP, 88% of MLP and 63% of GMP gave uni-lineage 149 
output (Fig. 2b). When there was uni-lineage output, 92% of LMPP cells had lymphoid output 150 
(B or NK) and 8% myeloid output (G or M). The MLP was virtually exclusively a lymphoid 151 
progenitor with very low myeloid output (3%). 79% of GMP cells had myeloid and 21% 152 
lymphoid output. Bi-lineage output was detected in 24% of LMPP, 12% of MLP and 33% of 153 
GMP (Fig. 2c) and output of three or more lineages was rare (6% of LMPP, 0% of MLP and 154 
3% of GMP) (Fig. 2d). Only 8% of all plated LMPPs, 7% of GMPs and hardly any MLPs 155 
(0.3%) exhibited combined lympho-myeloid potential (Fig. 2e). Lympho-myeloid output from 156 
LMPP was significantly higher compared to GMP (p=0.0125) and MLP (p=0.0019, 157 
Supplementary Table 3c).  158 
We also tested lympho-myeloid (B, NK, G, M) potential of 96 LMPPs, 52 MLPs and 110 159 
GMPs as single cells, in a third in vitro liquid culture assay, on MS5 stroma with SCF, IL7, 160 
thrombopoietin (TPO), IL2, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), 161 
G-CSF and Macrophage Colony Stimulating Factor (M-CSF) (S7T2GM/G/M condition) that 162 
was used to define the MLP21 (Supplementary Fig. 2b). Similar results to SGF15/2 condition 163 
were obtained but S7T2GM/G/M condition was less permissive for granulocytic output 164 
(Supplementary Fig. 2e-i, Supplementary Table 3d). Most output from LMPP was uni-165 
lineage with rarer bi-lineage and less frequent multi-lineage outputs. MLP exhibited only 166 
lymphoid uni-lineage output. 167 
Finally, we assessed the lympho-myeloid potential of 215 LMPP, 197 MLP and 219 GMP 168 
single cells in a fourth assay, with an independent culture condition, optimized for detecting 169 
combined lymphoid (B, NK, T) and myeloid (M, G) potential. Single LMPP, MLP and GMP 170 
were cultured on MS-5/hDL-1IND stroma with SCF, FLT3L, IL7 (condition SF7b/Dox) and the 171 
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B-NK-M-G output was analyzed at 3 weeks and the T cell output at 6 weeks (Fig. 2f-j, 172 
Supplementary Table 3e). Uni-lineage T cell output was detected in LMPP and MLP 173 
populations (3% of positive wells) but was virtually absent in GMP (<0.1%) (Fig. 2g). T cell 174 
combined with other lymphoid output was detected in 1-5% of LMPP and MLP and rarely in 175 
GMP (Fig. 2g). Lympho-myeloid output was only detected in LMPP (14%) (Fig. 2i). Overall, 176 
24 functionally different progenitor types were identified in the three single cell in vitro clonal 177 
assays; all 24 progenitor types were observed in the LMPP and only subsets of them were 178 
seen in MLP and GMP (Supplementary Fig. 2j). 179 
Ossicle assay defines the in vivo potential of LMPP, MLP and GMP  180 
Successful single cell transplantation of human progenitors in xenotransplantation assays is 181 
not feasible. Furthermore, direct injection of progenitor cell populations into immunodeficient 182 
mice yields low (<0.1%) engraftment15, 21, 22, 25. Therefore, we tested in vivo progenitor 183 
function in new humanized ossicle model34. Human BM-derived mesenchymal stromal cells 184 
were subcutaneously injected into immunodeficient mice, where over 8 weeks they form a 185 
humanized ossicle. LMPP, MLP and GMP progenitors were injected into the ossicle and 186 
lineage output was analyzed 1 and 2 weeks post-injection (Supplementary Fig. 3a-b). 187 
Engraftment was detected at both time points, with greater hCD45+hCD33+hCD14+ (M), 188 
hCD45+hCD33+hCD15+ (G) and hCD45+hCD33-hCD19+ (B) engraftment at week 2 compared 189 
to week one (data not shown). All subsequent analyses were done at 2 weeks post-190 
transplantation. As the number of cells injected varied (~300-60,000 cells depending on the 191 
progenitor subset, Supplementary Fig. 3c), we report mean cell engraftment per 1000 192 
transplanted cells. GMPs had the highest mean engraftment (2.6%), followed by LMPP 193 
(1.4%) and MLP (0.2%). LMPP produced more CD33+ myeloid cells (82%) than CD19+ B 194 
cells (17%) (Fig 3b-c). MLP generated more B cells (78±5.9%) than myeloid cells (19±6.7%) 195 
(Fig 3b-c). There was no correlation between the number of the transplanted cells and the 196 
lympho-myeloid ratio (Supplementary Fig. 3d). GMP generated mainly myeloid cells (97%, 197 
Fig. 3b-c). Myeloid cells generated from LMPP and GMP expressed monocytic (CD14) and 198 
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granulocytic (CD15) markers. No CD14+ and/or CD15+ cells were detected from MLPs (Fig. 199 
3c). Morphology analysis of the engrafted cells confirmed CD15+ cells were granulocytic and 200 
CD14+ monocytic (Fig. 3d), Double positive CD14+CD15+ cells, generated by LMPP and 201 
GMP (Fig. 3c), were more immature myeloid cells by morphology (Fig. 3d). Thus, LMPP, 202 
MLP and GMP have different lymphoid and myeloid potentials in the humanized ossicle 203 
assay. 204 
Transcriptional programs of LMPP, MLP and GMP correlate with their functional 205 
potential 206 
We performed RNA-sequencing of human CB HSPC populations (HSC, MPP, LMPP, MLP, 207 
CMP, GMP and MEP). Hierarchical clustering using all expressed genes separated LMPP 208 
and MLP from the other HSPCs. HSC and MPP clustered away from mature progenitors (Fig. 209 
4a and Supplementary Fig. 4a). We used ANOVA analysis to obtain differentially expressed 210 
genes (DEG) between HSPC populations (Supplementary Table 4). We performed principal 211 
component analysis (PCA), using all expressed genes or between 300 to 10000 of the most 212 
DEG (Fig. 4b). The best separation of HSPC populations on a PCA plot was achieved using 213 
the 300 most DEG (Fig. 4b). Principal component (PC) 1 separated HSPCs by lineage 214 
potential and PC2 by maturation. By comparing the eigenvalues of the 300 most DEG with 215 
those from a randomized data set, we demonstrated that PCs 1-3 captured most of the 216 
variation between populations (Supplementary Fig. 4b-c). We also identified genes with 217 
highest variance across all populations without assuming population identity. PCA plot using 218 
this gene set gave similar results (Fig. 4b and Supplementary Fig. 4d). The loadings plot for 219 
the PCA using the ANOVA define 300 most DEG identified stem- (HLF, MECOM, NFIB), 220 
lymphoid- (IGJ, IRF8, MME) and erythroid-megakaryocytic-affiliated genes (HBD, HPGDS) 221 
(Fig. 4c). Hierarchical clustering using the 300 ANOVA gene set separated HSPC 222 
populations (Fig. 4d). ELANE, MPO and PRTN3 were most strongly expressed in the GMP, 223 
whereas the LMPP and MLP shared expression of many lymphoid-affiliated genes (e.g. IL7R, 224 
LCK, SYK, ADA, HLX, LST1 and ITGAL). 225 
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Transcriptional relatedness between HSPC populations, without assuming any hierarchical 226 
relationships, was further analyzed through pairwise comparisons (Fig. 4e, Supplementary 227 
Fig. 4e, Supplementary Table 5-11). The most closely related populations were HSC and 228 
MPP (only 13 separating DEG), while LMPP and MLP were closely related (85 DEG). GMP 229 
were most closely related to the CMP (40 DEG), but retained a similarity to LMPP (183 DEG). 230 
We derived gene expression signatures for LMPP, MLP and GMP from DEG in one versus all 231 
population comparisons, filtered for uniquely expressed genes (Fig. 4f, Supplementary 232 
Table 12a-c). The GMP signature contained many myeloid genes and the MLP signature 233 
many lymphoid genes (Fig. 4d). By contrast, the LMPP signature contained both lymphoid 234 
(ETS1, EBF1, CYTIP) and myeloid genes (TRPM2, S100A8, PADI4, ALOX15B).  235 
To validate these findings, we investigated the profiles of LMPP, GMP and MLP using 236 
recently published gene sets25. GMP expressed immature myeloid genes whereas LMPP and 237 
MLP expressed genes affiliated with B cells, monocytes and DCs, but not neutrophils (with 238 
the exception of FOSB) (Supplementary Fig. 4f). Additionally, the GMP was enriched for 239 
MetaCore pathways associated with myeloid maturation (e.g. granulocyte development: 240 
FDR=0.0136), whereas MLP was enriched for lymphopoiesis pathways (e.g. Notch signaling: 241 
FDR<0.001). The LMPP had more balanced enrichment for both lymphoid and myeloid 242 
pathways (e.g. M-CSF signaling: FDR<0.001 and BCR signaling: FDR=0.049) 243 
(Supplementary Table 13).  244 
We used two approaches to pinpoint transcription factors (TFs) driving these programs. First, 245 
we identified TFs differentially expressed between the MLP and GMP (Supplementary Fig. 246 
4g). Second, we examined expression of previously identified hematopoietic TFs35 (Fig. 4g). 247 
In both analyses, GMP expressed mainly myeloid TFs (e.g. ERG, GATA2, MYB, EGR1), 248 
while lymphoid TFs (e.g. HES1, RUNX3, POU2F2, LEF1, IKZF1, IRF8, TCF4) showed 249 
highest expression in MLP. LMPP showed balanced expression of both myeloid and 250 
lymphoid TFs. A similar trend was seen with cytokine and chemokine receptor genes 251 
(Supplementary Fig. 4h). Therefore, the transcriptional programs of LMPP, MLP and GMP 252 
reflect their functional potentials. 253 
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Single cell RNA analyses reveals a continuum of differentiation  254 
To begin to separate distinct progenitors within the heterogeneous GMP, LMPP and MLP 255 
populations, we index flow sorted single cells for functional analysis, RNA-sequencing and 256 
quantitative RT-PCR (qRT-PCR). Index data allowed correlation of function and 257 
transcriptional state36 (Fig. 5a). First, we profiled expression of 96 genes, encoding lineage-258 
affiliated transcriptional regulators, cell surface and lineage-affiliated markers 259 
(Supplementary Table 14), in a total of 919 single LMPPs, MLPs and GMPs. Genes with low 260 
variance and levels of detection were excluded. Expression of 74 genes was taken forward 261 
for analysis. Hierarchical clustering assigned GMPs, LMPPs and MLPs to three clusters 262 
(Supplementary Fig. 5a-b). Cluster 1 (543 cells) was mainly MLPs and LMPPs, cluster 2 263 
(150 cells) was a mix of GMPs, LMPPs and MLPs, and cluster 3 (226 cells) mainly GMPs. 264 
Cluster 1 showed higher expression of lymphoid-affiliated genes, cluster 3 showed increased 265 
expression of myeloid genes (Supplementary Fig. 5b). Cluster 2 had a mixed lympho-266 
myeloid expression profile. The cellular composition in each gene expression cluster mirrored 267 
the single cell functional output (Supplementary Fig. 5b).  268 
We performed dimensionality reduction on gene expression data using a diffusion map 269 
method adapted for single cell data37,38. By indicating progenitor identity on the diffusion map 270 
(Supplementary Fig. 5c), MLP, LMPP and GMP cells form a continuum in agreement with 271 
the hierarchical clustering (Supplementary Fig. 5a). Next, we colored the diffusion map by 272 
cluster assignment (Supplementary Fig. 5c). Cluster 2 was positioned between clusters 1 273 
and 3, in agreement with its mixed lympho-myeloid transcriptional signature (Supplementary 274 
Fig. 5b).  275 
To overcome gene selection bias in qRT-PCR data, we performed single cell RNA-276 
sequencing and correlated this with function of 91 LMPP, 110 MLP and 119 GMP from two 277 
different donors (157 and 163 from each donor). Clustering using the combined gene set, 278 
variable in both donors, identified 3 clusters (Fig. 5b and Supplementary Fig. 5d). Most 279 
cluster 1 cells were MLP; most cluster 3 cells were GMP, while cluster 2 was comprised of 280 
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LMPP and GMP cells (Supplementary Fig. 5e). Cluster 1 showed high expression of 281 
lymphoid-affiliated genes (e.g. MME, JCHAIN and ABCA1). Cluster 3 showed increased 282 
expression of myeloid genes (e.g. CPA3, MPO and VIM). Cluster 2 showed a mixed 283 
transcriptional signature and increased expression of hematopoietic progenitor gene KIT. 284 
PCA revealed a transcriptional continuum of LMPP, MLP and GMP populations (Fig. 5c-d). 285 
Identical analysis on the second donor provided similar conclusions (Supplementary Fig. 286 
5f). Overall, single cell transcriptional profiles of the LMPP, MLP and GMP suggest a 287 
continuum of lympho-myeloid differentiation in the currently defined LMPP, MLP and GMP. 288 
Refined sorting strategies further purify the LMPP and GMP 289 
As our data showed that current flow sorting does not purify functionally homogenous 290 
populations, we correlated surface marker expression with function in the LMPPs and GMPs 291 
as they showed the greatest functional heterogeneity. Flow indexing data showed that single 292 
LMPP cells with lymphoid output had significantly higher CD10 and CD45RA expression 293 
compared to those with myeloid and lympho-myeloid output (Fig. 6a-b; CD10: Ly vs Ly-My 294 
p=0.0052, Ly vs My p=0.027; CD45RA: Ly vs Ly-My p=4.8x10-6, Ly vs My p=0.0027, 295 
Wilcoxon rank sum test). This was confirmed by higher CD10 expression in single LMPPs in 296 
lymphoid-biased cluster 1, compared to myeloid-biased cluster 3 (Supplementary Fig. 6a). 297 
Therefore, we developed a new LMPP flow sorting strategy to purify CD10hi CD45RAhi LMPP, 298 
here termed LMPPly, and CD10loCD45RAlo LMPPs, hereafter LMPPmix (Supplementary Fig. 299 
6b), aiming to maximize the lymphoid-only and mixed myeloid and lympho-myeloid potential, 300 
respectively. 26% of total LMPP were LMPPly and 27% LMPPmix (Fig. 6c). When cultured in 301 
SGF15/2 conditions and analyzed after 2 weeks, LMPPly had significantly lower cloning 302 
efficiency compared to LMPP and LMPPmix but significantly higher than MLP (Fig. 6d and 303 
Supplementary Table 15; Fisher’s exact test p<0.0001 for all comparisons). LMPPly were 304 
lymphoid progenitors with virtually no myeloid potential and significantly lower myeloid 305 
potential than LMPP and LMPPmix (Fig. 6d and Supplementary Table 15; Fisher’s exact test 306 
p=0.0496 and p=0.0280 respectively). LMPPly had very small residual (1.6%) lymphoid-307 
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myeloid potential (Fig. 6h). LMPPmix cells retained virtually all the myeloid potential and most 308 
of the lympho-myeloid potential (Fig. 6e-h and Supplementary Table 15). This suggests that 309 
functionally LMPPly were intermediate between LMPP and MLP. This was confirmed using a 310 
second in vitro culture condition (SF7b) (Fig. 6i, Supplementary Fig. 6c-f and 311 
Supplementary Table 15). 312 
Based on flow indexing data, GMPs with myeloid-only output had significantly higher CD38 313 
expression compared to those with lympho-myeloid or lymphoid output (Fig. 7a-b) 314 
(p=1.57x10-11 and p=1.6x10-8 respectively, Wilcoxon rank sum test). Concordantly, CD38 315 
expression in single GMPs in cluster 3 (highest myeloid potential) had significantly higher 316 
CD38 expression compared to GMPs in clusters 1 (highest lymphoid potential) and 2 317 
(lymphoid and myeloid potential). (Supplementary Fig. 6g). There was a significant positive 318 
correlation between CD38 expression and myeloid gene expression (MPO) and negative 319 
correlation between CD38 and lymphoid gene expression (MME and SELL) by single cell 320 
qRT-PCR (p=2.2x10-16, ρ=0.53 (MPO), p=7.1x10-5, ρ=-0.22 (MME), p=1.3x10-5, ρ=-0.24 321 
(SELL), Spearman’s rank correlation coefficient, Supplementary Fig. 6h). To purify a GMP 322 
sub-population without lymphoid potential based on CD38 expression, we divided the entire 323 
Lin-CD34+ population into CD38hi (44% of CD38+), CD38lo (15% of CD38-) and CD38mid (area 324 
between the two new gates) (Fig. 7c, Supplementary Fig. 6i). CD38hi, CD38mid and CD38lo 325 
cells were further purified to isolate GMP CD38hi, CD38mid (CD38midCD45RA+CD10-) and 326 
LMPP CD38lo. LMPP CD38lo cells were rare (1 in 108 MNCs) and no conclusions could be 327 
reached about their functional potential. The in vitro lineage potential of single GMP CD38hi 328 
(279 cells) and CD38mid (693 cells) was compared to conventionally purified LMPP (1136 329 
cells) and GMP cells (1622) using the SGF15/2 condition. Whereas the GMP CD38hi and 330 
LMPP had a similar cloning efficiency of ~55%, the GMP and CD38mid had a slightly higher 331 
cloning efficiency of ~70% (Fig. 7d). All four populations produced principally uni-lineage 332 
output (63-72%) (Fig. 7e). Compared to conventionally purified GMP, GMP CD38hi had 333 
drastically reduced lymphoid (Fisher’s exact test p<0.0001) and lympho-myeloid potential 334 
(Fisher’s exact test p=0.0115) (Fig. 7e-h and Supplementary Table 15), indicating a 335 
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functionally purer population. In summary, the refined sorting strategy enabled purification of 336 
functionally homogeneous populations. 337 
Taken together, all our single cell observations suggest the progenitor hierarchy downstream 338 
of stem cells may be more complex than previous models have suggested (Supplementary 339 
Fig. 7). 340 
 341 
Discussion 342 
Here we report on the prospective separation and direct comparison of freshly isolated CB 343 
LMPP, MLP and GMP. Our results show these lympho-myeloid progenitors were functionally 344 
and transcriptionally distinct and heterogeneous at the single cell level. Though uni-lineage 345 
progenitors were most abundant, rarer multi-lineage lympho-myeloid progenitors were 346 
detected, most frequently in the LMPP. Single cell transcriptional analysis showed that 347 
LMPP, MLP and GMP form a transcriptional continuum, with MLP arcing from a lymphoid 348 
pole, and GMP from a myeloid pole, to intersect with the LMPP, positioned in the middle. By 349 
combining functional and transcriptional analyses with flow cytometric index data, we devised 350 
new flow purification strategies to isolate more functionally homogeneous populations within 351 
existing LMPP and GMP. 352 
Several issues have prevented a clear understanding of previously identified human lympho-353 
myeloid progenitors. First, these progenitors have been isolated using cell surface markers 354 
based on historical precedent rather than marker purifying to functional homogeneity. 355 
Second, prospectively isolated lympho-myeloid progenitor populations have never previously 356 
been systematically compared. Third, it is unclear if early progenitor populations downstream 357 
of HSC contain only uni-lineage cells16, 25 or also bi- and multi-lineage progenitors in the 358 
mouse5, 14, 17, 18, 26, 39 or human21, 22, 23, 24. Fourth, functional assays demonstrate potential 359 
rather than actual cell fate in vivo in steady state conditions. Finally, failure to register 360 
functional potential may reflect the inadequacy of an assay rather than the true potential, or 361 
indeed fate, of the cell in vivo. Thus, there is uncertainty about how distinct the differently 362 
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identified progenitors are and if distinct, what their comparative functional potentials and 363 
transcriptional programs are at a clonal level. 364 
Our exhaustive analysis of 4598 single LMPPs, MLPs and GMPs, as well as populations of 365 
these progenitors, showed that they were functionally different in vitro and in vivo when 366 
transplanted in mice with humanized ossicles. The novel humanized ossicle model allowed 367 
~10-100-fold more human cell output than reported previously21, 23, 25. The GMP was primarily 368 
a myeloid progenitor with residual B and NK cell potential. Residual lymphoid potential could 369 
be virtually eliminated by purifying the highest 44% of CD38-expressing GMP cells. The MLP 370 
was primarily a B, NK and T cell progenitor with residual monocyte output. The LMPP had 371 
lymphoid and myeloid potential. Our new flow purification scheme divided the LMPP into two 372 
populations based on CD10 and CD45RA: one was almost entirely lymphoid, the other 373 
captured most of the myeloid/lympho-myeloid potential. Interestingly, the LMPP produced 374 
mainly myeloid cells in vivo. Humanized ossicles may be particularly efficient at promoting 375 
human myelopoiesis, unlike naive NSG mice, which better supports lymphopoiesis.  376 
We detected 24 different lineage-affiliated potentials in lympho-myeloid progenitors, a likely 377 
underestimate, as we did not test for eosinophil, mast cell, basophil and dendritic cell 378 
function. Though the majority of progenitors were uni-lineage, bi- and multi-lineage output 379 
was seen (up to 39% and 13%, respectively, of cells in vitro). Lympho-myeloid lineage 380 
decisions could occur at multiple levels at the HSC1, 2, 3, MPP5, 14 and presumably more 381 
mature LMPP17, 18, 26, MLP and GMP39 populations. Within the LMPP and GMP, true lympho-382 
myeloid progenitors could be rare (up to 10-14% of cells) and concentrated in the LMPP. 383 
Importantly, no experiments so far have directly examined the hierarchical relationships 384 
between lineage-biased HSC, MPP and lympho-myeloid progenitors. Quantitative differences 385 
in multi- versus uni-lineage output have been observed between fetal liver and BM in the 386 
broad CD34+CD38± populations16. All our data was in CB and similar experiments to those 387 
described here, will be needed to determine the ratio of uni-lineage versus bi- and multi-388 
lineage progenitors in BM.  389 
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One separate question is whether diverse lineage-affiliated progenitors identified in vitro have 390 
stably different functions or whether there is plasticity such that functional output may be 391 
stochastically determined, or variably instructed. Further single cell functional analysis on 392 
potentially functionally purer populations will be required with detailed fate mapping in mice.  393 
The rarity of LMPP and MLP (2/105 BM MNCs and 1/104 CB MNCs) and the minor proportion 394 
of multi- and bi-lineage progenitors within the LMPP prompted us to study large numbers of 395 
single cells to obtain robust information on rare bi- and multi-lineage potentials. The rarity of 396 
the LMPP is also noteworthy for two reasons. First, single cell RNA-sequencing programs39 of 397 
unfractionated MNCs will have to sequence large numbers of cells to provide adequate 398 
representation of these rare progenitors. Second, in acute myeloid leukemia (AML), 399 
leukaemic stem cells (LSC) are often arrested at an LMPP-like stage, where they can 400 
comprise up to 80% of MNCs22. Given this, we speculate that the small pool size of normal 401 
LMPP may be very tightly controlled to minimize oncogenic transformation. Additionally, 402 
understanding how normal LMPPs differentiate may provide insight into novel differentiating 403 
therapies for AML LMPP LSC. 404 
Methods  405 
Methods, including statements of data availability and any associated accession codes and 406 
references, are available in the online version of the paper. 407 
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Figure legends 524 
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Figure 1. Human CB lympho-myeloid populations have distinct functional potential in 525 
vitro. (a) Cloning efficiency and lineage affiliation of myelo-erythroid colonies in a CFU assay 526 
(150 CB HSPCs plated). Error bars are ± SD. n=5. CFU-mix, mixed erythro-myeloid colony; 527 
CFU-M, monocyte/macrophage colony; CFU-G, granulocyte colony; CFU-GM, granulocyte 528 
and monocyte/macrophage colony; E, erythroid colony (BFU-E and CFU-E). (b) Morphology 529 
of May-Grunwald-Giemsa stained cells from CFU assay (left, bar size 10 µm) and flow 530 
cytometric plots of cells harvested from indicated colony types (right). (c) Lineage output after 531 
culturing 150 LMPP, MLP and GMP cells for 1, 2 or 3 weeks on MS-5 stroma with SCF, G-532 
CSF, FLT3L, IL15, IL2 and DuP-697. Data represent mean from 3 CB donors ± SD. Flow 533 
cytometric plots for two week cultures shown in Supplementary Fig. 1b. (d) Gene 534 
expression analysis of flow cytometric-purified output cells from (c). (e) T cell output after 535 
culturing LMPP, MLP and GMP cells in bulk for 5 or 7 weeks on OP9-hDL1 stroma with SCF, 536 
FLT3L and IL7. Data represent percentage from hCD45+ cells from 5 CB donors (mean± 537 
1SD). DN, CD7+CD1a+ CD4-CD8-; DP, CD7+CD1a+CD4+CD8+; CD4, CD7+CD1a+CD4+CD8-; 538 
CD8, CD7+CD1a+CD4-CD8+. Flow cytometric plots for 5 week cultures shown in 539 
Supplementary Fig. 1c. (f) Gene expression analysis from flow-purified output cells from (e) 540 
and control mature non-T cells, obtained from sorting cells from E, G and M colonies. 541 
Figure 2. CB LMPP and GMP are lympho-myeloid progenitors, while MLP is mainly a 542 
lymphoid progenitor in clonal in vitro assays. (a) Total cloning efficiency (left) of single 543 
LMPP, MLP and GMP in SGF15/2 condition (LMPP: 615/1136 cells, MLP: 76/710, GMP: 544 
1145/1622). Significance defined by Fisher’s exact test. Cloning efficiency of lymphoid (Ly, 545 
middle) and myeloid lineages (My, right). Bars indicate total cloning efficiency; filled portion 546 
indicates the proportion of lymphoid (lymphoid plus mixed) or myeloid potential (myeloid plus 547 
mixed clones). Mean ± SD is shown. Significance is defined using students t-test. (b) Single-, 548 
(c) bi- and (d) multi-lineage outputs from single cells, presented as a percentage of positive 549 
wells in SGF15/2 condition. (e) Lymphoid (Ly), myeloid (My) and lympho-myeloid (Ly-My) 550 
outputs presented as a percentage of all plated cells in SGF15/2 condition. (f) Total cloning 551 
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efficiency (left) of single cell progenitors in SF7b/Dox condition (LMPP: 128/215 cells, MLP: 552 
37/197, GMP: 127/219). Cloning efficiency of lymphoid (middle) and myeloid lineages (right). 553 
Bars indicate total cloning efficiency; filled portion indicates the proportion of lymphoid or 554 
myeloid potential. Mean ± SD is shown. Significance is defined as in (a). (g) Single-, (h) bi- 555 
and (i) multi-lineage outputs from single cells, presented as a percentage of the positive wells 556 
in SF7b/Dox condition. (j) Lymphoid (Ly), myeloid (My) and lympho-myeloid (Ly-My) outputs 557 
presented as a percentage of all plated cells in SF7b/Dox condition. For the single cell assay 558 
in SGF15/2 condition: 22 CB donors; SF7b/Dox condition: 3 CB donors. 559 
Figure 3. Human CB LMPP, MLP and GMP progenitors have distinct differentiation 560 
potential in vivo. (a) Percentage human engraftment 2 weeks after progenitor 561 
transplantation, normalized to 1000 transplanted cells. (b) Percentage B and myeloid cells 562 
within human CD45+/HLA-ABC+ cells. (c) Representative flow cytometric plots of percentage 563 
human engraftment (CD45+HLA-ABC+), B cells (CD19+) and myeloid cells (CD33+), and 564 
percentage CD14+ and CD15+ myeloid cells 2 weeks after transplantation. Frequencies 565 
shown are an average from 11 CB donors for LMPP, 3 from MLP, 6 for GMP. (d) 566 
Representative images of May-Grunwald-Giemsa stained CD15+, CD15+/CD14+ and CD14+ 567 
myeloid cells generated by LMPP 2 weeks after transplantation, n=2. 568 
Figure 4. Distinct transcriptional patterns of human CB HSPC populations. (a) 569 
Hierarchical clustering of HSPC populations using all genes and 1000 bootstrap permutation 570 
analyses; “au” = approximate unbiased p-values. Height values expressed as (1- [correlation 571 
co-efficient]). (b) PCA plots showing CB HSPC when using varying number of ANOVA genes 572 
(ranked by ANOVA p-value) and 300 most variant genes (bottom right). Percentage variance 573 
represented by each Principal Component (PC) is shown. (c) Loadings plot, showing the 574 
genes with the most extreme loadings scores for the PCA run with top 300 ANOVA (top) or 575 
variant (bottom) genes. (d) Heatmap showing hierarchical clustering and the expression of 576 
the top 300 ANOVA genes by HSPC populations. Clusters highlighted in yellow show distinct 577 
expression patterns across HSPC populations. Expression values are normalized per gene. 578 
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(e) Summary of all differentially expressed genes between HSPC populations. (f-g) 579 
Heatmaps showing the expression of top 50 genes from the LMPP, MLP and GMP gene 580 
signatures (f) and transcription factors differentially expressed across HSPC populations (g). 581 
Genes affiliated with the lymphoid or myeloid lineages have color-coded asterix (lymphoid: 582 
orange, myeloid: green) and genes associated with immune function are labeled with black 583 
asterix. Expression values are normalized per gene. RNA seq data come from 4 CB donors 584 
(MPP: 3 donors). 585 
Figure 5. Transcriptional heterogeneity of CB lympho-myeloid progenitor cells from 586 
single cell RNA-sequencing. (a) Experimental scheme used to combine single cell 587 
functional analysis, single cell RNA-sequencing and single cell qRT-PCR based on flow 588 
cytometric index data. (b) Heatmap showing clustering of single LMPP, GMP and MLP using 589 
the 55 most highly and variably expressed genes between clusters. Heatmap shows 590 
clustering from one of two donors analyzed. Data from the other donor are in Supplementary 591 
Fig. 5d. Log-normalized gene expression (rows) for each single cell (columns) is shown. (c-592 
d) PCA plot colored by cell type (c) or cluster membership (d). 593 
Figure 6. New flow sorting strategy to purify functional potential within CB LMPP 594 
compartment. (a) Logicle transformed CD10 and CD45RA surface marker levels in LMPPs, 595 
grouped by functional output. Ly - uni-lymphoid (B or NK) or bi-lymphoid output (B+NK), My - 596 
uni-myeloid (M or G) or bi-myeloid output (M+G), Ly-My - lympho-myeloid output. n=2 CB 597 
donors. (b) CD10 and CD45RA expression levels in LMPPs, measured by flow cytometry, 598 
colored by output from functional assays. Logicle-transformed data are from 2 CB donors. (c) 599 
Revised sorting strategy based on CD10 and CD45RA expression levels defined by 600 
bioinformatic analyses. Representative plots from 6 CB donors. (d) Total cloning efficiency 601 
(left) of single MLP, LMPP, LMPPly, LMPPmix and GMP in SGF15/2 condition (LMPPly: 56/244 602 
cells, LMPPmix: 152/240). Significance defined using Fisher’s exact test. Cloning efficiency of 603 
lymphoid (Ly, middle) and myeloid lineages (My, right). Bars indicate total cloning efficiency; 604 
filled portion indicates the proportion of lymphoid potential (lymphoid plus mixed) or myeloid 605 
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potential (myeloid plus mixed clones). Mean ± SD is shown. Significance is defined using 606 
students t-test. (e) Single-, (f) bi- and (g) multi-lineage outputs from single cells in SGF15/2 607 
condition, presented as percentage of the positive wells. (h) Lymphoid (Ly), myeloid (My) and 608 
lympho-myeloid (Ly-My) outputs presented as percentage of all plated cells in SGF15/2 609 
condition.  (i) Lymphoid (Ly), myeloid (My) and lympho-myeloid (Ly-My) outputs presented as 610 
percentage of all plated MLP, LMPP, LMPPly, LMPPmix and GMP cells in SF7b condition.  For 611 
SGF15/2 condition (d-h) data are from 6 CB donors (for LMPP, MLP and GMP controls - 22 612 
CB donors (the same shown in Fig. 2a-e)). For SF7b condition (i) - 6 CB donors (for LMPP, 613 
MLP and GMP 9 CB donors (including 3 CB donors in Fig. 2f-j)). 614 
Figure 7. New flow cytometric sorting strategy to purify functional potential within CB 615 
GMP compartment. (a) Logicle transformed CD38 surface marker expression levels in 616 
GMPs, grouped by functional output. n=5 CB donors. (b) CD38 and CD34 levels in GMPs 617 
colored by output from functional assays. Data are from 5 CB donors. (c) Revised sorting 618 
strategy, based on CD38 expression levels defined by bioinformatic analysis. Representative 619 
plots from 4 CB donors. (d) Total cloning efficiency (left) of the single GMP CD38hi, GMP, 620 
CD38mid and LMPP (GMPhi: 152/279 cells, CD38mid: 508/693). Significance defined using 621 
Fisher’s exact test. Cloning efficiency of lymphoid (Ly, middle) and myeloid lineages (My, 622 
right) of single cell GMP CD38hi, GMP, CD38mid and LMPP. Bars indicate total cloning 623 
efficiency; filled portion indicates the proportion of lymphoid (lymphoid plus mixed) or myeloid 624 
potential (myeloid plus mixed clones). Mean ± SD is shown. Significance is defined using 625 
students t-test. (e) Single-, (f) bi- and (g) multi-lineage outputs from single cells, presented as 626 
percentage of the positive wells. (h) Lymphoid (Ly), myeloid (My) and lympho-myeloid (Ly-627 
My) outputs presented as a percentage of all plated GMP CD38hi, GMP, CD38mid and LMPP 628 
cells. For the functional assays (d-h), data are from 4 CB donors, for LMPP and GMP 629 
controls data are from 22 CB donors (the same shown in Fig. 2a-e). 630 
 631 
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Normal and patient samples collection 633 
BM or CB samples from normal donors were obtained with informed consent (UK protocol 634 
MREC 06/Q1606/ or Administrative Panel on Human Subjects Research Institutional Review 635 
Board-approved protocols Stanford IRB no. 18329, no. 6453, and no. 5637). Fresh CB 636 
samples were purchased from NHS Cord Blood Bank, UK or from New York Blood Center. 637 
They were processed within 16-34h after collection. Mononuclear cells were isolated and 638 
CD34+ fraction was separated as described40. Fresh or frozen BM MNCs or CD34+ fractions 639 
were used. Human BM stromal cell were obtained from samples according to Medical 640 
University of Graz Ethikkommission (Institutional Review Board-approved protocol, MUG 641 
Graz IRB no. 19-252). BM mesenchymal stromal cells (MSCs) were isolated and expanded 642 
as described34. 643 
Flow cytometric sorting of HSPC populations 644 
Antibodies used for flow cytometric sorting and immunophenotyping are listed in 645 
Supplementary Table 16. CB or BM CD34+ enriched fraction was lineage depleted by 646 
staining with purified anti-human CD2, CD3, CD4, CD7, CD8a, CD11b, CD14, CD19, CD20, 647 
CD56, CD235a followed by Qdot 605 conjugated goat F(ab')2 anti-mouse IgG (H+L). Cells 648 
were also stained with anti-human CD38-FITC, CD45RA-PE or -BV650, CD123-PE Cy7, 649 
CD90-biotin, CD34-PerCP and CD10-APC. Finally, cells were incubated with streptavidin-650 
conjugated APC-eF780 and Hoechst 33258 (Invitrogen, Loughborough UK; final 651 
concentration: 1 μg/ml). For humanized ossicle xenotransplantation assay CD34+ CB was 652 
stained with the same panel of anti-human lineage antibodies and anti-CD16. All lineage-653 
antibodies were PE Cy5-conjugated. Cells were then stained with CD38-PE Cy7, CD90-FITC, 654 
CD123-PE, CD34-APC, CD10-APC Cy7, CD45RA-BV605 and propidium-iodide (Thermo 655 
Fisher, Waltham MA; final concentration: 1 μg/ml). Unstained, single stained and 656 
Fluorescence Minus One (FMO) controls were used to determine background staining and 657 
compensation in each channel. Single stained controls used anti-mouse compensation 658 
particle set (BD, Oxford UK). CB cells were sorted with average purity 99% for in vitro and 659 
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RNA assays and 96% for humanized ossicle xenotransplantation. Prior to single-cell sorts, 660 
single fluorescent beads were deposited directly to a 96-well plate to establish accuracy of 661 
single cell deposition (>99%). Sorting was performed on BD Aria III or BD Fusion and flow 662 
cytometric analysis was done on LSR Fortessa X20. Data analysis was performed using Diva 663 
v8.1 or FlowJo v10.0.06 and v10.0.07r2. 664 
Index sorting for functional and transcriptional analyses 665 
For index sorting we saved information on the following parameters: FSC, SSC, Hoechst and 666 
expression of Lineage markers, CD34, CD38, CD45RA, CD10, CD90 and CD123 for each 667 
single cell. For 919 index sorted single cells we tested expression of 96 genes qRT-PCR 668 
(Supplementary Fig. 5); 74 passed QC. Separately, we performed single cell index sorting 669 
and single cell in vitro functional assays on 3458 single cells (from Fig. 2, Supplementary 670 
Fig. 2, Fig. 6, Fig. 7, Supplementary Fig. 6). In separate experiments we index sorted 320 671 
single cells for single cell RNA seq (Fig. 5). Using common “position of the cells” in flow 672 
cytometric plots we could then map functional potential (i.e. lymphoid, myeloid or lympho-673 
myeloid) to gene expression and cell surface marker expression and forward/side scatter. To 674 
purify LMPPly and LMPPmix the thresholds were defined based on maximum CD10 and 675 
CD45RA expression of LMPPs with myeloid output. To purify GMP CD38hi thresholds were 676 
set using the maximum normalized CD38 level of GMPs with myeloid output and for lympho-677 
myeloid output. 678 
In vitro lympho-myeloid differentiation assays (bulk, single cell, limiting dilution assay) 679 
For population analysis, MS-5 cells were seeded on a 24-well plate coated with 0.1% gelatin 680 
at a density of 2x104 cells per well in α-MEM medium (Gibco/Thermo Fisher Scientific 681 
Loughborough UK) supplemented with 10% FBS (Hyclone, GE Healthcare, SH30070.03 682 
Amersham Hatfield, UK), 1% Penicillin-Streptomycin, 1% L-Glutamine, 10-7M DuP-697 683 
(Cayman Chemical, Ann Arbor, USA), 20 ng/ml SCF, 10 ng/ml G-CSF, 10 ng/ml FLT3L, 10 684 
ng/ml IL15 and 10 ng/ml IL2 (Peprotech London UK, SGF15/2 condition). 24h after plating of 685 
MS-5 cells, 150 highly purified LMPPs, MLPs or GMPs were deposited in each well. Medium 686 
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was half-changed every week. Harvested cells were flow cytometric analyzed at week 1, 2 687 
and 3. 688 
Limiting dilution assay (LDA) was performed by sorting LMPP, MLP or GMP cells at different 689 
cell doses (1, 2, 5, 10 and 20 cells) from 4 different CB samples into 96-well plates pre-plated 690 
with 2500 MS-5 cells per well with 100 µl of medium without cytokines. Immediately after 691 
sorting 100 µl of 2x SGF15/2 medium was added to each well. Medium was half-changed 692 
every week. A total of 833 LMPP, 789 MLP and 1252 GMP cells from 4 different CB samples 693 
were analyzed for the LDA at week 2 – 2.5 (Supplementary Table 2a). Frequency 694 
calculations were performed using L-Calc software (Stem Cell Technologies) and 695 
independently verified by ELDA software (http://bioinf.wehi.edu.au/software/elda/). The LDA 696 
plots were generated using R with lines representing the estimates calculated by ELDA 697 
software. 698 
For single cell analysis single LMPP, MLP and GMP cells were deposited into 96-well plates 699 
pre-plated with 2500 MS-5 cells per well with 100 µl of medium without cytokines. Medium 700 
with 2x cytokines was added to each well after sorting. Medium was half-changed every 701 
week. After culture for 2-2.5 weeks flow cytometric analysis was performed and wells with 702 
more than 15 human CD15+, CD14+, CD56+ or CD19+ cells were scored positive (details in 703 
Supplementary Table 2b). To compare with previous published conditions21, single cell 704 
LMPP, MLP and GMPs were cultured for 4 weeks on MS-5 stroma in H5100 medium 705 
(StemCell Technologies Cambridge UK) supplemented with 100 ng/ml SCF, 20 ng/ml IL-7, 50 706 
ng/ml TPO, 10 ng/ml IL-2, 20 ng/ml GM-CSF, 20 ng/ml G-CSF and 10 ng/ml M-CSF (all from 707 
Peprotech, S7T2GM/G/M condition) and analyzed by flow cytometric. 708 
To read lineage readouts for all in vitro lympho-myeloid differentiation assays, harvested cells 709 
were stained with anti-human CD15-FITC, CD14-PE, CD19-PE Cy7, CD56-APC or -PE Cy5, 710 
CD45-APC Cy7 and in some cases with CD34-BV605.  711 
In vitro T cell differentiation assay 712 
OP9-hDL1 cells41 were seeded on a 24-well plate coated with 0.1% gelatin at a density of 713 
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2x104 cells per well in freshly prepared α-MEM medium (Gibco/Thermo Fisher Scientific, 714 
12000-063) with 20% heat-inactivated FBS (Hyclone, GE Healthcare, SH30070.03 715 
Amersham Hatfield, UK), 1% Penicillin-Streptomycin, 1% L-Glutamine, 10 ng/ml SCF, 5 ng/ml 716 
FLT3L and 5 ng/ml IL7 (Peprotech, London, UK, SF7a condition). 24h after OP9-hDL1 cell 717 
plating, 150 highly purified LMPP, MLP or GMP cells were deposited in each well. Cells were 718 
dissociated from wells and transferred to new plates with fresh OP9-hDL1 cells weekly. 719 
Harvested cells were flow cytometric analyzed at week 4, 5 and 7. Cells were stained with 720 
anti-human CD7-FITC, CD1a-PE, CD8-PE Cy7, CD4-APC and CD45-APC Cy7. 721 
In vitro combined T-lympho-myeloid differentiation assay 722 
MS5-hDL1IND100 cells42 (where hDL1 expression could be induced by adding doxycycline) 723 
were seeded on 96-well plates coated with 0.1% gelatin at a density of 2500 cells per well in 724 
100 µl freshly prepared -MEM medium (Gibco/Thermo Fisher Scientific, Loughborough UK) 725 
supplemented with 20% FBS (Hyclone, GE Healthcare, SH30070.03HI, Amersham Hatfield, 726 
UK), 1% Penicillin-Streptomycin, 1% L-Glutamine. 24h after plating of MS5-hDL1IND cells, 727 
single cell LMPP, MLP or GMP cells were deposited into each well and cultured in the 728 
presence of 20nM Insulin  (Sigma-Aldrich, St Louis, MO), 50 ng/ml SCF, 20 ng/ml FLT3L and 729 
10ng/ml IL7 (Peprotech London UK, SF7b condition). Fresh medium was added every 730 
week. 731 
Cells were harvested at 21 days and split into two, half of them were used for flow cytometric 732 
analysis and the remaining half were re-seeded on MS5-hDL1IND100 cells and cultured in 733 
SF7b/Dox condition with doxycycline (1 μg/ml). Medium was half-changed twice every week. 734 
Fresh doxycycline was added to the cultures 3 times a week. At 42 days cells were harvested 735 
and flow cytometric analysis was performed. At 21 days wells with more than 8 human 736 
CD15+, CD14+, CD56+ or CD19+ cells were scored positive. At 42 days flow cytometric 737 
analysis using CD1a, CD7, CD4 and CD8 antibodies was performed and wells with more 738 
than 8 CD7+ cells were scored positive for T cells. 739 
Colony Forming Unit assays 740 
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Colony formation was tested as before22. Colony identity was confirmed morphologically after 741 
cytospin (medium acceleration, 800 rpm 5 min May-Grunwald Giemsa stain (Sigma, Poole 742 
UK) and by flow cytometry with anti-human CD15-FITC, CD14-PE, CD235a-PE Cy5.  743 
Humanized ossicle xenotransplantation assay 744 
Protocol was performed as previously described34. In brief, in vitro expanded human BM-745 
MSCs were harvested, resuspended in 60 μl of pooled human platelet lysate (pHPL) and 746 
admixed with 240 μl of matrigel-equivalent matrix. The wholematrix-cell mixtures were 747 
injected subcutaneously to generate humanized ossicle niches. 8-10 weeks post BM-MSC 748 
application transplants were evaluated for bone and marrow formation. Mice with established 749 
humanized ossicle niches were conditioned with 200 rad of irradiation 12-24 hours prior to 750 
transplantation. Different numbers of LMPP, MLP and GMP cells from at least 3 different CB 751 
donors (Supplementary Fig. 3c) were transplanted in total volume of 20 μl by direct 752 
intraossicle injection. Experiments were performed in accordance with a protocol approved by 753 
Stanford’s Administrative Panel on Laboratory Animal Care (no. 22264) and in adherence to 754 
the US National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. 755 
Normal multi-lineage engraftment was assessed 1-2 weeks after transplantation and 756 
defined by the presence of myeloid cells (CD33+) and B cells (CD19+) among engrafted 757 
human CD45+HLA-ABC+ cells. Engrafted mice were antibody stained with CD14-PE or -758 
APC Cy7, CD15-FITC, HLA-ABC-FITC or -PB, CD19-APC, CD33-PE, CD45-V450. 759 
RNA sequencing of bulk HSPC populations 760 
100 highly purified HSPCs from normal CB samples were sorted directly into lysis buffer in 761 
RNAse inhibitor (Clontech St Germain-en-Laye France) and stored at -80°C before further 762 
processing. cDNA synthesis was done with Smarter Ultra low input RNA kit v1 (Clontech) as 763 
previously described43. Illumina libraries were generated using Nextera XT DNA sample 764 
preparation kit and Index Kit (Illumina Chesterford UK). Library size and quality were checked 765 
using Agilent High-Sensitivity DNA chip with Agilent Bioanalyser (Agilent Technologies 766 
Stockport UK). Concentration of indexed libraries was determined using Qubit High-767 
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Sensitivity DNA kit (Invitrogen Loughborough, UK). Libraries were pooled to a final 768 
concentration of 5-14 nM and were sequenced on an Illumina HiSeq 2000 single-end 50bp 769 
reads. 770 
Bulk and single cell gene expression analysis by Dynamic Arrays 771 
Gene expression analysis was performed as described40. TaqMan assays (Applied 772 
Biosystems) are listed in Supplementary Table 2 and 8.  773 
Single cell RNA sequencing 774 
Single cell libraries for RNA sequencing were prepared using the Smart-seq2 protocol44, 775 
where 23 cycles were used for the cDNA library preamplification. Illumina Nextera XT DNA 776 
sample preparation kit and Index Kit (Illumina Chesterford UK) was used for cDNA 777 
tagmentation and indexing. ERCC RNA Spike-In Mix (Ambion) was added to the lysis mix at 778 
a final dilution of 1:80,000,000. Library size, quality and concentration were checked as done 779 
for the bulk RNA sequencing. Libraries were pooled to a final concentration of 7-28 nM and 780 
78 to 95 single cell libraries were combined per pool. Sequencing was done on HiSeq4000 781 
using 75bp paired-end reads. Each pool contained a library generated from an empty well. 782 
Bioinformatic analysis (bulk RNA seq, single cell Biomark and single cell RNA seq) 783 
For 50 bp single end bulk RNA sequencing, alignment to the hg38 reference genome was 784 
carried out using TopHat v2.0.1045. Alignments were processed using Picard tools 785 
(http://picard.sourceforge. net/). We used R version 3.1.1 http://www.R-project.org. 786 
Sequencing reads were filtered for mapq 4 i.e. uniquely mapping reads. This gave a range of 787 
15.1 x 106 to 56.2 x 106 aligned reads. The total number of genes expressed per sample was 788 
calculated as an rpkm>1. The number of expressed genes ranged from 7,707 to 11,350, with 789 
an average of 9,800. The count matrix was transformed to log2(cpm) scale and Principal 790 
Component Analysis was carried out. An ANOVA-like test was performed, using edgeR 791 
package for R, to identify differentially expressed genes between the populations. One CB 792 
biological replicate MPP population was excluded because when compared to the 3 793 
remaining MPP biological replicates its global gene expression showed higher number of 794 
uniquely expressed genes and low correlation to the other three replicates. The genes were 795 
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ranked by their significance (p-value adjusted for multiple testing) and different numbers of 796 
genes were used for PCA and hierarchical clustering of samples. Eigenvalues from PCA 797 
were calculated by using the square of the standard deviation of the principle components. 798 
Differential gene expression for one versus one and one versus all comparisons were 799 
calculated using edgeR. For gene signature generation a cut-off of logFC>1 was used and 800 
genes ranked based on p-value. Heatmaps and associated hierarchical clustering were 801 
generated using GENE-E software (Broad Institute) or using the R packages pvclust and 802 
heatmap.2 (gplots). MetaCore Pathway Map (Thomson Reuters, London UK) enrichment 803 
analysis was carried out on genes differentially expressed by each lympho-myeloid 804 
population versus all other populations (one versus all). A p-value cut-off of 0.05 was used to 805 
identify positively enriched pathway maps.  806 
Analysis of single cell Biomark data was performed in R version 3.3.1 using data exported 807 
from the Fluidigm Data Collection software. For quality control, amplification curves with a 808 
Quality Score of <0.65 and any Ct values >27 were treated as undetected expression. Any 809 
cells where expression of both B2M and GAPDH housekeeping genes was not detected were 810 
removed from further analysis (n=7). An additional cell was removed as it had a high outlying 811 
number of genes detected. Housekeeping gene ACTB was also measured in the assay, but 812 
unlike B2M and GAPDH did not show robust expression across the majority of cells and 813 
therefore was not used in further analysis. Normalized ∆Ct values were calculated by 814 
subtracting the mean of Ct values for B2M and GAPDH in each cell, as previously 815 
described19. Housekeeping genes were excluded from further analysis. Genes detected in 816 
<20 cells, with variance <1 across all cells or expressed in none of the MLP, GMP or LMPP 817 
10 cell control samples assayed by qRT-PCR alongside single-cell samples were removed 818 
from downstream analysis. Post quality control data measured 74 genes in 919 single cells.  819 
Hierarchical clustering was performed on genes and cells by using the hclust function (stats 820 
package) with distance measure 1 – Spearman’s correlation and agglomeration method 821 
Ward.D2. The heatmap visualizing the clustering was plotted using the heatmap.2 function 822 
(gplots package). Cells were divided into three clusters using the cutree function (stats 823 
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package) on the hierarchical clustering. A gene was classed as differentially expressed 824 
between two clusters if it satisfied two criteria: 1) the magnitude of the log2 fold change of 825 
mean ∆Ct in each cluster was >1 and 2) the adjusted p-value (Benjamini & Hochberg 826 
correction for multiple testing) of 2-sided Wilcox test of ∆Ct expression values between the 827 
two clusters was < 0.01. Diffusion maps46 were used for dimensionality reduction of the single 828 
cell gene expression data. This method was implemented using the DiffusionMap function 829 
from the destiny R package with Euclidean distance37, 47. 830 
Single cell RNA sequencing reads were aligned using G-SNAP48 and mapped reads were 831 
assigned to Ensembl genes (release 8149) by using HTSeq50. Cells with fewer than 500,000 832 
reads mapping to nuclear genes, greater than 20% of mapped reads mapping to 833 
mitochondrial genes, greater than 20% of mapped reads mapping to External RNA Controls 834 
Consortium (ERCC) spike-ins or with expression of fewer than 750 different genes with at 835 
least 10 counts were removed from further analysis. ERCC spike-in controls identified genes 836 
exceeding technical variance51. From donors 1 and 2, 163/166 and 157/249 cells passed 837 
quality control, respectively. Single cell profiles were normalized using the scran R package52 838 
and variable genes were identified as having variation exceeding technical levels51. Data 839 
showed batch effects between different donors. The Seurat R package 840 
(https://github.com/satijalab/seurat) was then used to regress out plate effects from the 841 
sequencing data, and set more stringent thresholds for variable genes, leading to 1,605 842 
variable genes in donor 1 and 1,273 variable genes in donor 2. Principal component analysis 843 
was performed using Seurat, and clusters found using the Seurat::FindClusters function on 844 
the first 10 principal components. Heatmaps display the top genes marking these clusters as 845 
identified by the Seurat::FindAllMarkers function and were visualized using the 846 
gplots::heatmap.2 function. 847 
Statistical analysis 848 
Frequency of populations in flow cytometric plots gates is the mean of the population across 849 
all samples analyzed as indicated. Bar graphs of gene expression analysis represent mean 850 
+/-SEM or +/-SD as indicated. Two-tailed students unpaired t-test and Fisher's exact test 851 
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(Excel, GraphPad sortware) were used to determine statistical significance in gene 852 
expression analysis data and single cell functional assays respectively. The statistical 853 
significance of the P-value was defined as follows for all P-value comparisons made: P>0.05 854 
- not significant, P =0.01-0.05 - significant (*), P= 0.001-0.01 - very significant (**), P<0.001 - 855 
extremely significant (***). Wilcoxon rank sum test was done using R. Kruskal-Wallis test, 856 
stratified by group was used to define significant differences between LMPP, MLP and GMP 857 
in the single cell functional assay in SGF15/2 condition and gave the following p-values: 858 
LMPP - 5x10-6, MLP - 0.1725, GMP - 0.7395. Wilcoxon rank sum test confirmed that there 859 
was no outlier among single cell LMPPs coming from different CB donors. Prism software 860 
was used to plot the gene expression analysis and single cell in vitro data. LDA plots were 861 
generated using R and the lines represent the estimates calculated using ELDA software. 862 
A Life Sciences Reporting Summary for this paper is available. 863 
Data availability 864 
Bulk RNA sequencing data have been deposited in Arrayexpress 865 
(https://www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-5456. Single cell RNA 866 
sequencing data accession number: GSE100618. All other source data that support the 867 
findings of this study are available from the corresponding author upon request. 868 
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Table 1 Frequencies of lineage outputs from limiting 
dilution assay (LDA) 
Frequency LMPP MLP GMP 
B 2 11 22 
NK 3 18 8 
M 5 194 2 
G 10 394 4 
B_NK 6 38 31 
M_G 16 ND 7 
B_M 10 392 32 
B_G 13 789 38 
M_NK 9 392 11 
NK_G 15 ND 17 
B_NK_M 16 392 44 
B_NK_G 18 ND 49 
B_M_G 22 ND 43 
NK_M_G 23 ND 20 
B_NK_M_G 29 ND 56 
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